

## GENOMMA LAB INFORMS THE TERMS AND AMOUNT FOR THE EXTENSION OF THE REVOLVING DEBT SECURITIES PROGRAM (CEBUR)

**Mexico City, April 16, 2019 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)** (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence, informs the terms and amount to be approved at the Annual General Shareholders' Meeting for the new revolving bond facility.

The amount to be proposed for shareholder approval is 10.0 billion Mexican Pesos. This new “Recurring Debt Issuer Program” for up to 10 billion pesos will have similar terms as the previous program approved in 2013 (the previous program had a maximum amount of 8.0 billion Mexican Pesos and expired in 2018). The main difference between the new program and the 2013 program is that the new program will allow Genomma to issue short-term debt, which could be used for working capital needs, while also permitting the issuance of long-term debt that could be used to refinance existing debt.

The program is not an issuance in itself, but a mechanism to speed up a new issuance to refinance existing debt, when needed. Currently, Genomma has no immediate needs for issuing any debt under the new proposed program. Having the approval of shareholders would allow management to secure refinancing in a highly efficient way in the Debt Capital Markets.

The “Recurring Debt Issuer Program” (*Programa de Emisor Recurrente*) represents a Regulatory facility to speed up the issuance of debt in the Mexican Bolsa. This program will be valid for the next 5 years. The previous “5-year Issuer Program” that expired in 2018, at its peak reached 5.5 billion Mexican Pesos, far below the maximum amount (8.0 million Mexican Pesos).

As of today, outstanding amount on Cebures is 3.95 billion Mexican Pesos. Current gross financial debt is 5.87 billion Mexican Pesos (Net debt is 4.46 billion Mexican Pesos, representing a Net Debt to EBITDA ratio of less than 2.0 times).

By approving the new “Recurring Debt Issuer Program”, the Company will have access to refinance its long-term and short-term financial debt in the Debt Capital Markets, with no intention to increase gross financial debt in the short to mid-term (other than the undisbursed portion of the long-term loan for the manufacturing facility granted by the IFC and the IDB Institutions). Any issuance of local bonds for refinance will be with the goal to decrease financial expense (spread) or to improve maturity of the debt structure.

---

### About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

For more information visit: [www.genommalab.com](http://www.genommalab.com)

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker “**LABB**” (**Bloomberg: LABB:MM**).

### Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.